放射性药物领域的成长机会

大型製药企业日益增长的兴趣推动了行业创新势头。

本报告涵盖诊断放射学（包括PET、SPECT）和放射性药物（包括α疗法、β疗法、Auger疗法和治疗诊断学）的临床试验评估。报告还涵盖了各领域的主要企业及其在放射性药物行业中扮演的角色。

本报告重点在于能够提昇放射性药物性能的技术创新。放射性药物产业目前正处于高信心阶段的初期，投资者、合约研发生产机构（CDMO）和大型製药企业积极参与资金筹措、授权合约、收购和策略联盟等活动。本研究深入分析了有助于放射性药物产业发展的伙伴关係、协作、併购以及私人资金筹措活动。

本报告解答的关键问题包括：

• 放射性药物研发的关键驱动因素和挑战是什么？
• 各细分市场的临床研发进度如何？
• 哪些是正在研发创新放射性药物的关键产业参与者？
• 放射性药物的资金筹措合作环境如何？
• 放射性药物有哪些成长机会？

目录

战略问题

• 为什么经济成长变得越来越困难？
• The Strategic Imperative 8
• 三大战略挑战对产业的影响
• 成长引擎由成长机会驱动
• 调查方法

成长机会分析

• 分析范围
• 分割

成长要素

• 成长驱动因素
• 成长抑制因素
• 引言：放射性药物正日益受到关注

放射诊断

• 放射诊断
• 肿瘤学中的PET分析
• 用于PET成像的放射性药物
• SPECT放射诊断分析
• 关键创新：放射学

放射治疗药物

• 放射治疗药物
• 放射线治疗的比较分析
• 放射治疗产品线概览
• 放射性药物的关键趋势
• 放射性药物：创新者风采
• 放射性药物的技术创新
• 标靶化策略和放射化学的进展：创新
• 新型放射性同位素：创新
• 药物输送技术：创新

战略洞察

• 放射治疗药物的私人资金筹措
• 放射性药物收购趋势概述
• 放射性药物的合作关係
• 关键见解
• 全球併购和联盟趋势
• 世界地图上的放射性药物公司
• 来自放射性药物专家的见解

成长机会领域

• 成长机会 1：专注于 Alpha 疗法
• 增长机会2：聚焦放射治疗药物
• 成长机会 3：专注于新目标

附录

• 用于PET成像的放射性药物
• 主要产业公司临床研发管线分析：放射治疗
• 技术成熟度等级（TRL）解释

未来计划

• 成长机会带来的益处和影响
• 未来计划
• 免责声明

Emerging Interest from Big Pharma Players Is Pushing Industry Innovation Momentum

The report covers the clinical trial assessment for radiodiagnostics, including PET, SPECT, and radiopharmaceuticals, comprising Alpha therapy, Beta therapy, Auger Therapy, and Theranostics. The report covers the key players in each space and their contributions to the radiopharmaceuticals landscape.

The report sheds light on technology innovations to make better radiopharmaceuticals. The radiopharmaceuticals industry is at the cusp of a high-confidence phase, with investors, CDMOs, and big pharmaceutical firms engaging in fundraising rounds, licensing agreements, acquisitions, and strategic collaborations. This research provides insights into partnerships, collaborations, acquisitions/mergers, and private funding activities that contribute to the growth of radiopharmaceuticals.

Key questions this report answers: What are the key drivers and challenges for the development of radiopharmaceuticals? What is the pace of clinical development in each segment? Who are the leading industry participants developing innovative radiopharmaceuticals? What does the funding and partnership landscape look like for radiopharmaceuticals? What are the growth opportunities in radiopharmaceuticals?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8
• The Impact of the Top 3 Strategic Imperatives on the Industry
• Growth Opportunities Fuel the Growth Pipeline Engine
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation

Growth Generator

• Growth Drivers
• Growth Restraints
• Introduction: Radiopharmaceuticals Gaining Traction

Radiodiagnostics

• Radiodiagnostics
• PET Analysis for Oncology
• PET Imaging Radiopharmaceuticals
• SPECT Analysis for Radio Diagnostics
• Key Innovators-Radiodiagnostics

Radiotherapeutics

• Radiotherapeutics
• Comparative Analysis of Radiotherapies
• Overview of the Radiotherapeutics Pipeline
• Key Trends in Radiopharmaceuticals
• Radiopharmaceuticals-Innovator Spotlight
• Technological Innovation in Radiopharmaceuticals
• Targeting Strategies and Radiochemistry Advances-Innovations
• Novel Radioisotopes-Innovations
• Drug Delivery-Innovations

Strategic Insights

• Private Funding for Radiotherapeutics
• Overview of the Acquisition Landscape for Radiopharmaceuticals
• Partnership Landscape in Radiopharmaceuticals
• Key Insights
• Global M&A; Partnerships Landscape
• Radiopharma Companies on Global Map
• Insights from Radiopharmaceuticals Experts

Growth Opportunity Universe

• Growth Opportunity 1: Focus on Alpha Therapies
• Growth Opportunity 2: Focus on Radiotherapeutics
• Growth Opportunity 3: Focus on Novel Targets

Appendix

• PET Imaging Radiopharmaceuticals
• Clinical Pipeline Analysis of Key Industry Players-Radiotherapeutics
• Technology Readiness Levels TRL: Explanation

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Legal Disclaimer